MX2018005129A - Agonistas del receptor de glucagon. - Google Patents

Agonistas del receptor de glucagon.

Info

Publication number
MX2018005129A
MX2018005129A MX2018005129A MX2018005129A MX2018005129A MX 2018005129 A MX2018005129 A MX 2018005129A MX 2018005129 A MX2018005129 A MX 2018005129A MX 2018005129 A MX2018005129 A MX 2018005129A MX 2018005129 A MX2018005129 A MX 2018005129A
Authority
MX
Mexico
Prior art keywords
glucagon receptor
receptor agonists
glucagon
native
compounds
Prior art date
Application number
MX2018005129A
Other languages
English (en)
Inventor
Alsina-Fernandez Jorge
Coskun Tamer
Original Assignee
Elanco Us Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Us Inc filed Critical Elanco Us Inc
Publication of MX2018005129A publication Critical patent/MX2018005129A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos con una duración de acción prolongada en el receptor de glucagón en comparación con el glucagón nativo. Se proporcionan en forma específica agonistas del receptor de glucagón con modificaciones en la estructura del glucagón nativo introducidas para agonizar selectivamente el receptor de glucagón durante un período de tiempo prolongado.
MX2018005129A 2015-10-26 2016-10-14 Agonistas del receptor de glucagon. MX2018005129A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246199P 2015-10-26 2015-10-26
PCT/US2016/056969 WO2017074715A1 (en) 2015-10-26 2016-10-14 Glucagon receptor agonists

Publications (1)

Publication Number Publication Date
MX2018005129A true MX2018005129A (es) 2018-06-06

Family

ID=57200152

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005129A MX2018005129A (es) 2015-10-26 2016-10-14 Agonistas del receptor de glucagon.
MX2018005132A MX2018005132A (es) 2015-10-26 2016-10-14 Agonistas del receptor de glucagon.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018005132A MX2018005132A (es) 2015-10-26 2016-10-14 Agonistas del receptor de glucagon.

Country Status (25)

Country Link
US (3) US9884093B2 (es)
EP (2) EP3368061B1 (es)
JP (3) JP6321299B2 (es)
KR (1) KR20180053747A (es)
CN (2) CN108135981B (es)
AR (2) AR106318A1 (es)
AU (2) AU2016344434B2 (es)
BR (2) BR112018006920A2 (es)
CA (2) CA3003242C (es)
DK (1) DK3368060T3 (es)
EA (2) EA201890676A1 (es)
ES (2) ES2747908T3 (es)
HR (1) HRP20201353T1 (es)
HU (1) HUE050859T2 (es)
IL (1) IL258092A (es)
LT (1) LT3368060T (es)
MX (2) MX2018005129A (es)
NZ (1) NZ740644A (es)
PL (2) PL3368060T3 (es)
PT (2) PT3368060T (es)
RS (1) RS60567B1 (es)
SI (1) SI3368060T1 (es)
TW (1) TWI622596B (es)
WO (2) WO2017074715A1 (es)
ZA (2) ZA201801756B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR20180108602A (ko) 2015-12-23 2018-10-04 암젠 인크 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US20200384119A1 (en) * 2017-06-21 2020-12-10 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
TW201920240A (zh) * 2017-08-09 2019-06-01 法商賽諾菲公司 用於脂肪肝病和脂肪性肝炎治療的ｇｌｐ－１／胰高血糖素受體激動劑
MX2020002977A (es) 2017-09-22 2020-11-06 Regeneron Pharma Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
WO2019140025A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140024A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
WO2019140021A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
EP3826662A1 (en) * 2018-07-23 2021-06-02 Eli Lilly and Company Method of using a gip/glp1 co-agonist for diabetes
KR20200038878A (ko) * 2018-10-04 2020-04-14 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도
HRP20230929T1 (hr) 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
KR20210091230A (ko) * 2018-11-12 2021-07-21 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
US20200268835A1 (en) * 2019-02-27 2020-08-27 Novo Nordisk A/S Compounds For Use in NASH
JP7111917B2 (ja) * 2019-06-28 2022-08-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
MX2023008330A (es) 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004932A (en) 1997-03-06 1999-12-21 Iowa State University Research Foundation, Inc. Use of glucagon as a metabolic conditioner for dairy cows and other ruminants
EA008831B1 (ru) 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc PEPTIDE ANALOGUES 1 LIKE LONG-ACTING GLUCAGON-LIKE
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
EA020326B9 (ru) 2008-06-17 2015-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
MX2010012695A (es) 2008-06-17 2011-03-15 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
RU2550696C2 (ru) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Основанные на амидах пролекарства пептидов глюкагонового надсемейства
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
JP6054861B2 (ja) 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
WO2011131646A1 (en) * 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES EXPRESSING G PROTEIN-COUPLED RECEPTOR ACTIVITY
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
MX2013011175A (es) 2011-03-28 2013-11-01 Novo Nordisk As Analogos de glucagon novedosos.
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
JP6396211B2 (ja) * 2011-07-04 2018-09-26 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
BR112014006684A2 (pt) 2011-09-23 2017-03-28 Novo Nordisk As análogos de glucagon
CN104144696A (zh) * 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
BR112014031671A2 (pt) 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
MY170671A (en) * 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
EP2895506A1 (en) 2012-09-17 2015-07-22 Imperial Innovations Limited Peptide analogues of glucagon and glp1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
KR20150096433A (ko) 2012-12-21 2015-08-24 사노피 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
JP6230352B2 (ja) 2013-09-19 2017-11-15 ユニ・チャーム株式会社 動物用排泄物処理材の製造方法および製造装置
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HUE039616T2 (hu) 2013-10-17 2019-01-28 Zealand Pharma As Acilezett glükagon analógok
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US20150150643A1 (en) * 2013-12-02 2015-06-04 The Johns Hopkins University Personalized computational modeling of atrial fibrosis to guide catheter ablation of atrial fibrillation
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080155A1 (en) * 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080149A1 (en) * 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
AR098614A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Compuesto para el tratamiento de hipoglicemia severa
AR098615A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
JP2017509603A (ja) * 2014-02-18 2017-04-06 ノヴォ ノルディスク アー／エス 安定なグルカゴン類似体及び低血糖症の処置のための使用
TW201625669A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016108586A1 (ko) 2014-12-30 2016-07-07 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
WO2016198604A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
PE20240215A1 (es) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑

Also Published As

Publication number Publication date
CA3000538A1 (en) 2017-05-04
JP2018504376A (ja) 2018-02-15
JP6354017B2 (ja) 2018-07-11
PT3368060T (pt) 2020-09-01
PT3368061T (pt) 2019-10-28
EP3368061A1 (en) 2018-09-05
HUE050859T2 (hu) 2021-01-28
AU2016344433B2 (en) 2018-12-06
CA3003242C (en) 2022-08-09
CN108135981A (zh) 2018-06-08
EP3368060A1 (en) 2018-09-05
AR106318A1 (es) 2018-01-03
US20170112904A1 (en) 2017-04-27
KR20180053747A (ko) 2018-05-23
AU2016344433A1 (en) 2018-04-19
CN108135981B (zh) 2022-04-15
JP7211712B2 (ja) 2023-01-24
MX2018005132A (es) 2018-06-06
WO2017074714A1 (en) 2017-05-04
JP2018508464A (ja) 2018-03-29
NZ740644A (en) 2019-10-25
JP2018135346A (ja) 2018-08-30
WO2017074715A1 (en) 2017-05-04
HRP20201353T1 (hr) 2020-11-27
ES2809548T3 (es) 2021-03-04
US9764004B2 (en) 2017-09-19
ZA201801756B (en) 2019-10-30
US20180104312A1 (en) 2018-04-19
IL258092A (en) 2018-05-31
EP3368061B1 (en) 2019-08-07
US20170114115A1 (en) 2017-04-27
ZA201802371B (en) 2020-01-29
SI3368060T1 (sl) 2020-08-31
PL3368061T3 (pl) 2020-03-31
EA038330B1 (ru) 2021-08-10
CN108348583A (zh) 2018-07-31
ES2747908T3 (es) 2020-03-12
LT3368060T (lt) 2020-08-25
EA201890634A1 (ru) 2018-10-31
EA201890676A1 (ru) 2019-01-31
DK3368060T3 (da) 2020-08-24
PL3368060T3 (pl) 2021-01-11
RS60567B1 (sr) 2020-08-31
AR106325A1 (es) 2018-01-03
CA3003242A1 (en) 2017-05-04
TWI622596B (zh) 2018-05-01
US9884093B2 (en) 2018-02-06
TW201726717A (zh) 2017-08-01
BR112018006920A2 (pt) 2018-11-06
CN108348583B (zh) 2022-06-03
EP3368060B1 (en) 2020-06-24
JP6321299B2 (ja) 2018-05-09
AU2016344434B2 (en) 2019-06-06
AU2016344434A1 (en) 2018-06-07
BR112018007225A2 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
MX2018005132A (es) Agonistas del receptor de glucagon.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
HK1255163A1 (zh) 作為apj受體激動劑的雜芳基羥基嘧啶酮
IL248347B (en) Compounds and preparations as agonists of toll-like receptor 7
IL248311B (en) Compounds and preparations as agonists of toll-like receptor 7
ZA201807350B (en) Novel compounds as gpr119 agonists
TR201910057T4 (tr) Kauçuk bi̇leşi̇mleri̇
IL252882B (en) History of benzoic acid bicycloheteroaryl-heteroaryls as beta-retinoic acid receptor agonists
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
HK1246184A1 (zh) 作為a7-烟碱乙酰膽碱受體激動劑的氨基苯並惡唑化合物
IL253848A0 (en) Amine compounds as 5-hydroxytryptamine 4 receptor agonists
PH12018501844A1 (en) Liraglutide in cardiovascular conditions
GB201603263D0 (en) Biomarkers for response to bip (rasolvir)
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
TH1601003483A (th) สารประกอบอินดาโซลในฐานะอะกอนิสต์ของ 5-ht4 รีเซปเตอร์

Legal Events

Date Code Title Description
FG Grant or registration